DK0542979T3 - Therapeutic composition for slow release of magnesium - Google Patents

Therapeutic composition for slow release of magnesium

Info

Publication number
DK0542979T3
DK0542979T3 DK92912677T DK92912677T DK0542979T3 DK 0542979 T3 DK0542979 T3 DK 0542979T3 DK 92912677 T DK92912677 T DK 92912677T DK 92912677 T DK92912677 T DK 92912677T DK 0542979 T3 DK0542979 T3 DK 0542979T3
Authority
DK
Denmark
Prior art keywords
magnesium
weight
mgo
parts
source
Prior art date
Application number
DK92912677T
Other languages
Danish (da)
Inventor
Fabienne Joanny
Original Assignee
Fabienne Joanny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabienne Joanny filed Critical Fabienne Joanny
Application granted granted Critical
Publication of DK0542979T3 publication Critical patent/DK0542979T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a new therapeutic composition useful for magnesic deficiencies to enterically release the magnesium contained therein in a slow and continuous way, said composition being characterized in that it is comprised of a mixture containing, in association with a physiologically acceptable vehicle, (A) from 4 to 14 parts by weight of magnesium from a magnesium source comprised of MgO, MgCl2? and the magnesium chloride hydrates having the formula MgCl2?, nH2?O where n is an integer or fractional number higher than 0 and not exceeding 6, and (B) from 6 to 13 parts by weight of a hydrophilic polymer, when the source of Mg is MgO, or from 10 to 30 parts by weight of a hydrophobic substance selected amongst the group including the physiologically acceptable hydrophobic polymers, the fatty acid esters and mixtures thereof, when the source Mg is different from MgO, the Mg content in said mixture being between 5 and 60 % by weight based on the weight of said mixture.
DK92912677T 1991-06-12 1992-06-12 Therapeutic composition for slow release of magnesium DK0542979T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9107141A FR2677546B1 (en) 1991-06-12 1991-06-12 THERAPEUTIC COMPOSITION FOR EXTENDED RELEASE OF MAGNESIUM.
PCT/FR1992/000534 WO1992022305A1 (en) 1991-06-12 1992-06-12 Therapeutic composition for sustained release of magnesium

Publications (1)

Publication Number Publication Date
DK0542979T3 true DK0542979T3 (en) 1999-01-04

Family

ID=9413736

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92912677T DK0542979T3 (en) 1991-06-12 1992-06-12 Therapeutic composition for slow release of magnesium

Country Status (8)

Country Link
EP (1) EP0542979B1 (en)
JP (1) JPH06503096A (en)
AT (1) ATE164071T1 (en)
DE (1) DE69224793T2 (en)
DK (1) DK0542979T3 (en)
ES (1) ES2117049T3 (en)
FR (1) FR2677546B1 (en)
WO (1) WO1992022305A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887492B2 (en) 2000-12-14 2005-05-03 Leiner Health Services Corp. Magnesium plus interactive agent delivery
FR2855412B1 (en) * 2003-05-27 2007-05-25 Menvielle Bourg Fabienn Joanny EXTENDED MAGNESIUM RELEASE COMPOSITION AND ITS APPLICATION IN THE THERAPEUTIC, COSMETIC AND NUTRITIONAL FIELD
FR2931359B1 (en) 2008-05-20 2012-12-21 Menvielle Bourg Fabienne Joanny USE OF MATRIX FOR EXTENDED RELEASE MAGNESIUM ORAL DELIVERY, AND COMPOSITION CONTAINING SAME
FR2931361B1 (en) 2008-05-20 2012-08-31 Menvielle Bourg Fabienne Joanny MAGNESIUM-BASED SYSTEM AND ITS USE IN COSMETICS
EP2813217A1 (en) 2013-06-11 2014-12-17 Fabienne Joanny Menvielle-Bourg Composition for oral administration of magnesium, in association with a composition for the treatment of type 2 diabetes and its complications

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422193A (en) * 1974-07-26 1976-01-21 Smith Kline French Lab Pharmaceutical compositions
CH677612A5 (en) * 1987-09-11 1991-06-14 Ciba Geigy Ag
GB8809421D0 (en) * 1988-04-21 1988-05-25 Fordonal Sa Antacid compositions with prolonged gastric residence time
US5002774A (en) * 1989-06-08 1991-03-26 Erbamont, Inc. Sustained release pharmaceutical tablet

Also Published As

Publication number Publication date
FR2677546A1 (en) 1992-12-18
FR2677546B1 (en) 1994-01-21
JPH06503096A (en) 1994-04-07
WO1992022305A1 (en) 1992-12-23
EP0542979B1 (en) 1998-03-18
EP0542979A1 (en) 1993-05-26
ATE164071T1 (en) 1998-04-15
DE69224793D1 (en) 1998-04-23
ES2117049T3 (en) 1998-08-01
DE69224793T2 (en) 1998-11-19

Similar Documents

Publication Publication Date Title
DE69206214D1 (en) New arylethylamine derivatives, processes for their preparation and pharmaceutical compositions containing them.
EE02958B1 (en) Prolonged - release preparation, polymer blend for its preparation and polymer blend preparation method
CA2009890A1 (en) Valproic acid
KR890004686A (en) Sustained release Etodolac
GB1520197A (en) Stable antibiotic compositions
IL111647A0 (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles, their preparation and pharmaceutical compositions containing them
HUP0300388A2 (en) Coating and binding agent for pharmaceutical formulations with improved storage stability
MY139606A (en) Sustained-release composition and process for producing the same
ES8207169A1 (en) 4-Amino-6,7-dimethoxy-2-piperazinylquinazoline derivatives, their preparation and use
DK0542979T3 (en) Therapeutic composition for slow release of magnesium
MX9307107A (en) COMPOSITION OF RETICULATED POLYMERS.
ES2174930T3 (en) METRONIDAZOL COMPOSITIONS OF MODIFIED LIBERATION AND METHODS TO PREPARE AND USE THE SAME.
BR9912706A (en) Pharmaceutical compositions containing ibuprofen and domperidone
CA2357114A1 (en) Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder
JPS5469154A (en) Antistatic finish of polyolefin
SU763396A1 (en) Rubber mixture
JPS55112202A (en) Antisticking composition for unvulcanized rubber
JPS5650958A (en) Resin composition
JPS5444034A (en) Easily absorbable nifedipine composition and anti- stenocardia containing said composition
JPS55164239A (en) Heat stabilizer composition for polyvinyl chloride
BR9303043A (en) METALLOTHERMAL REACTION MIXTURE
ES2079745T3 (en) EXPANDABLE STYRENE POLYMERS WITH A FIRST COATING, CONTAINING BISAMIDES.
JPS54132235A (en) Sublimable insecticide
JPS5746908A (en) Dental cement
JPS55118905A (en) Preparation of polymer or copolymer